98%
921
2 minutes
20
Background: Prostate cancer (PCa) is the most frequently diagnosed malignancy in men. It is the commonest cancer in Nigerian men. Multiparametric magnetic resonance imaging (mpMRI) is essential in the evaluation of patients with PCa.
Aim: To evaluate the clinicopathologic profile and pelvic MRI pattern of prostate cancer patients.
Methods: This was a retrospective study performed between July 2020 and June 2024. The study population was derived from men with histologically diagnosed PCa who subsequently had mpMRI for cancer staging. From the medical records, age, prebiopsy PSA, Gleason score (GS) and other relevant information were obtained.
Results: The records of 458 subjects were retrieved. A total number of 229 subjects had their prebiopsy PSA recorded while 158 subjects had their GS recorded. The mean age of the subjects was 66.38 ± 8.46 years, while the mean and median prebiopsy PSA were 49.37 ± 59.81 ng/ml and 33ng/ml, respectively. The mean GS of the subjects was 7.72 ± 1.29. The prostate capsule was the most commonly invaded structure (65.4%). The prevalence of bone metastasis was 22.8%, and the spine was the most commonly affected bone. Stage 3 and stage 4 disease were the most predominantly observed (58.4% and 32%, respectively). There was a statistically significant but weak correlation between tumor stage and GS.
Conclusion: The subjects' clinicopathologic profile and pelvic MRI findings show that patients commonly present with advanced prostate cancer in our environment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/njcp.njcp_766_24 | DOI Listing |
BMC Urol
September 2025
Department of Radiology, Osaka Proton Therapy Clinic, 1-27-9 Kasugade naka, Osaka konohana-ku, Osaka, 554-0022, Japan.
Int Urol Nephrol
September 2025
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.
View Article and Find Full Text PDFBr J Cancer
September 2025
Institute of Life Sciences, Bhubaneswar, Odisha, India.
Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.
Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, University of California Irvine, Irvine, CA, USA.
Eur Urol Focus
September 2025
Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.
Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).